Warning: mkdir(): Permission denied in /home/virtual/lib/view_data.php on line 81

Warning: fopen(upload/ip_log/ip_log_2024-06.txt): failed to open stream: No such file or directory in /home/virtual/lib/view_data.php on line 83

Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 84
Biochemical bone markers of bisphosphonate-related osteonecrosis of the jaw (BRONJ) and nonbisphosphonate drugs in osteonecrosis of the jaw

J Korean Dent Assoc > Volume 52(4); 2014 > Article
The Journal of The Korean Dental Association 2014;52(4):203-217.
Published online April 30, 2014.
임상가를 위한 특집 2 - Bisphosphonate-related osteonecrosis of the jaw(BRONJ)에 대한 biochemical bone markers와 악골괴사와 연관된 nonbisphosphonate drugs
이덕원1, 이현우2, 권용대3
1경희대학교 치의학전문대학원 구강악안면외과학교실, 난치성턱뼈질환센터
2경희대학교 치의학전문대학원 구강악안면외과학교실, 난치성턱뼈질환센터
3경희대학교 치의학전문대학원 구강악안면외과학교실, 난치성턱뼈질환센터
Biochemical bone markers of bisphosphonate-related osteonecrosis of the jaw (BRONJ) and nonbisphosphonate drugs in osteonecrosis of the jaw
Deok-Won Lee1, Hyun-Woo Lee2, Yong-Dae Kwon3
1Department of Oral and Maxillofacial Surgery, Center for Refractory Jawbone Diseases, School of Dentistry, Kyung Hee University
2Department of Oral and Maxillofacial Surgery, Center for Refractory Jawbone Diseases, School of Dentistry, Kyung Hee University
3Department of Oral and Maxillofacial Surgery, Center for Refractory Jawbone Diseases, School of Dentistry, Kyung Hee University
Abstract
Bisphosphonates are widely used in the treatment of many medical conditions, such as osteoporosis, multiple myeloma, Paget's disease, etc. However, side effect has been documented in the published data during the past years, osteonecrosis of the jaw in patients receiving long-term bisphosphonate therapy. Although pathogenesis of BRONJ(bisphophonate-related osteonecrosis of the jaw) is not yet fully understood, it is currently known to be a disease associated with suppressed bone turnover by bisphopbonate. Recent literature has indicated a similar association with nonbisphosphonate drugs used in cancer therapy including monoclonal antibodies denosumab and bevacizumab and multikinase inhibitor sunitinib. Accordingly, many studies have been carried out on the biochemical markers examination to assess the risk for BRONJ. The treatment of BRONI is reported with a review of the relevant literature. However, there is still a controversial discussion about the adequate treatment. It is necessary to accumulate further studies in order to establish more useful biochemical markers and effective treatment for BRONJ.
Key Words: Bisphosphonale-related osteonecrosis of the jaw(BRONJ);Biochemical bone marker;nonbisphosphonate drugs;


Editorial Office
Korean Dental Association, 257 Gwangnaru-ro, Seongdong-gu, Seoul 04802, Korea
Tel: +82-2-2024-9100   Fax: +82-2-468-4655/58   

Copyright © 2024 by Korean Dental Association.

Developed in M2PI